Trials / Active Not Recruiting
Active Not RecruitingNCT06564142
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Povetacicept in Adults With Immunoglobulin A Nephropathy (RAINIER)
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 605 (actual)
- Sponsor
- Alpine Immune Sciences Inc, A Subsidiary of Vertex · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of povetacicept in adult participants compared with placebo in reducing proteinuria and preserving renal function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Povetacicept | Subcutaneous injection administration. |
| DRUG | Placebo (matched to Povetacicept) | Placebo matched to Povetacicept subcutaneous injection administration. |
Timeline
- Start date
- 2024-08-30
- Primary completion
- 2028-01-30
- Completion
- 2028-01-30
- First posted
- 2024-08-21
- Last updated
- 2025-12-17
Locations
318 sites across 33 countries: United States, Australia, Austria, Belgium, Brazil, Canada, China, Croatia, Czechia, Denmark, Estonia, Finland, France, Germany, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Latvia, Lithuania, Mexico, Netherlands, Norway, Poland, Saudi Arabia, South Korea, Spain, Sweden, Taiwan, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06564142. Inclusion in this directory is not an endorsement.